TickerGuard
Buy Day today: Good (62) Broad market participation · no major macro event
IBRX

Immunitybio Inc

Healthcare · Biotechnology

8.50$ +7.0% vs. previous close Closing price · As of: Sep 17, 2026

Statements

Income Statement

Immunitybio Inc (IBRX) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (2025), "Revenue" came in at 113 million USD. Tick rows to compare them in a chart.

All figures in millions of USD.

Tick rows to compare them in a chart (up to 4)

Income Statement IBRX
Line item 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
0.6 0.2 0.0 0.0 0.0 0.0 0.6 0.9 0.2 0.6 15 113
0.3 -3.1 9.0 9.1 24 19 18 0.8
0.6 0.2 0.0 0.0 3.2 -9.0 0.6 0.9 0.2 0.6 15 113
1.6 11 27 40 53 49 140 196 248 232 190 208
4.3 228 95 57 28 18 27 135 103 123 169 150
5.9 238 121 94 89 58 221 331 352 363 359 369
-6.2 -239 -125 -99 -98 -67 -221 -330 -351 -362 -344 -256
0.0 0.0 0.1 0.6 0.4 5.9 9.1 15 47 87 132 113
-6.2 -237 -121 -97 -97 -66 -226 -350 -417 -584 -414 -352
0.0 -0.3 -0.6 -0.5 -0.5 -0.1 -1.8 0.0 0.0 0.0 0.1 -0.1
-6.2 -237 -121 -96 -96 -66 -222 -347 -417 -583 -414 -351
-5.7 -236 -118 -91 -87 -57 -204 -321 -352 -479 -264 -224

Data as of: September 17, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?